ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

3 years ago 382

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% successful premarket trading connected Friday aft the institution said that it had received support from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The institution said this is the archetypal caller cause to dainty the uncommon autoimmune illness successful a decade. ChemoCentryx's banal slipped 68.3% this year, portion the broader S&P 500 SPX, +0.83% is up 16.1%.

Read Entire Article